Bristol Myers Squibb Company
NEWS
Mavacamten is often referred to as “first-in-class” because it addresses the root cause of obstructions. Here’s everything you should know about its recent progress.
The 71st annual American College of Cardiology’s Scientific Session saw several wins over the weekend, led by some of the life sciences industries’ largest companies.
Pfizer stated that etrasimod patients achieved statistically significant improvements in primary endpoints of clinical remission and attained all secondary endpoints vs. placebo.
The FDA has a very busy week ending the month of March and moving into April, highlighted by a big AdCom vote on Amylyx’s ALS candidate AMX0035 on March 30.
Roche has partnered with BMS to utilize two digital pathology platforms that would advance research into solid tumor treatment options for patients.
The FDA delayed Bristol Myers Squibb’s (BMS) target date for Reblozyl, approved the company’s melanoma drug and Japan accepted BMS’ NDA for Breyanzi.
Bristol Myers Squibb Company forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.
BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina’s intellectual property lawsuit.
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
JOBS
IN THE PRESS